PMID- 35382966
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220927
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 36
IP  - 5
DP  - 2022 May
TI  - A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in 
      patients with type-2 Diabetes (ELAID study).
PG  - 108188
LID - S1056-8727(22)00082-4 [pii]
LID - 10.1016/j.jdiacomp.2022.108188 [doi]
AB  - BACKGROUND: Liraglutide is an effective treatment for the management of type 2 
      diabetes mellitus (T2DM). In addition to glycemic control and potential 
      cardioprotective effects, recent studies suggest a possible role for liraglutide 
      in the inhibition of platelet reactivity, further attenuating atherothrombotic 
      risk in patients with T2DM. We evaluated the in-vivo antiplatelet effect of 
      liraglutide in T2DM patients without macrovascular disease or concurrent 
      anti-platelet therapy. METHODS: A double-blind, placebo-controlled pilot study of 
      16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to 
      receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted. 
      Platelet aggregation studies at baseline and after initiation of the study 
      intervention: days 1, 7, and 14 and months 1, 3 and 6 were performed. RESULTS: 
      Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal 
      platelet aggregation responses although transient and significant attenuation in 
      maximum slope of platelet aggregation in response to collagen (p </= 0.05), 
      arachidonic acid (p </= 0.05) and ADP (p </= 0.02) was observed in liraglutide 
      compared to placebo treated patients in the first week. CONCLUSIONS: In this 
      pilot study of patients with T2DM liraglutide treatment was associated with a 
      significant, early and transient decrease in maximum slope of platelet 
      aggregation. The clinical significance of this effect is currently unknown and 
      may warrant further investigation. CLINICAL TRIAL REGISTRATION NUMBER: UTN 
      1111-1181-9567.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Loganathan, Jayasree
AU  - Loganathan J
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia.
FAU - Cohen, Adam C
AU  - Cohen AC
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia.
FAU - Kaloupis, Georgia M
AU  - Kaloupis GM
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia.
FAU - Harris, Carolyn
AU  - Harris C
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia.
FAU - Chronopoulos, Andriana
AU  - Chronopoulos A
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia.
FAU - James, Vanessa
AU  - James V
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia.
FAU - Hamilton, Justin
AU  - Hamilton J
AD  - Australian Centre for Blood Diseases, Monash University, Prahran, Melbourne, 
      Victoria, Australia.
FAU - Green, Sarah
AU  - Green S
AD  - Alfred Pathology Service, Alfred Health, Alfred Hospital, Melbourne, Victoria, 
      Australia.
FAU - Wallis, Andrew
AU  - Wallis A
AD  - Alfred Pathology Service, Alfred Health, Alfred Hospital, Melbourne, Victoria, 
      Australia.
FAU - Morgan, Susan
AU  - Morgan S
AD  - Alfred Pathology Service, Alfred Health, Alfred Hospital, Melbourne, Victoria, 
      Australia.
FAU - Dauer, Raymond
AU  - Dauer R
AD  - Department of Pathology, Eastern Health, Box Hill Hospital, Melbourne, Australia.
FAU - Gilfillan, Christopher
AU  - Gilfillan C
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia; Department of Endocrinology, Eastern Health, Box Hill Hospital, 
      Melbourne, Victoria, Australia.
FAU - Dear, Anthony E
AU  - Dear AE
AD  - Eastern Health Clinical School, Monash University, Melbourne, Victoria, 
      Australia. Electronic address: Anthony.dear@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20220330
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/chemically induced/complications/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Liraglutide/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
OTO - NOTNLM
OT  - Antiplatelet
OT  - Glucagon-like peptide-1 receptor (GLP-1R)
OT  - Liraglutide
OT  - Thrombosis
OT  - Type 2 diabetes mellitus
EDAT- 2022/04/07 06:00
MHDA- 2022/04/20 06:00
CRDT- 2022/04/06 05:22
PHST- 2022/01/27 00:00 [received]
PHST- 2022/03/24 00:00 [revised]
PHST- 2022/03/26 00:00 [accepted]
PHST- 2022/04/07 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2022/04/06 05:22 [entrez]
AID - S1056-8727(22)00082-4 [pii]
AID - 10.1016/j.jdiacomp.2022.108188 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2022 May;36(5):108188. doi: 
      10.1016/j.jdiacomp.2022.108188. Epub 2022 Mar 30.